Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2025
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. Following a May 2024 separation from its former parent (Inhibrx, Inc.) and a merger with a Sanofi subsidiary, the company operates as a standalone entity focused on two primary oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1,300 | $200 |
| Net Loss | $(140,055) | $1,687,572 (Net Income) |
| Operating Expenses | $136,325 | $331,648 |
| Cash and Cash Equivalents (Year End) | $124,220 | $152,596 |
| Long-Term Debt | $100,559 | $0 |
| Accumulated Deficit | $(246,187) | $(106,132) |
Note: 2024 Net Income was driven by a $2.0 billion non-cash gain related to the transaction with the Acquirer (Sanofi subsidiary) and the extinguishment of prior debt.
Material Changes vs. Prior Period
- Revenue: Increased 550% to $1.3 million, primarily due to a $1.3 million license fee from Scithera, Inc. recognized in Q2 2025.
- Operating Expenses: Decreased 59% to $136.3 million.
- R&D: Decreased 45% to $113.0 million, driven by the spin-off of the INBRX-101 program, termination of the INBRX-105 program, and reduced stock-based compensation (no acceleration of options in 2025 vs. $25.9 million in 2024).
- G&A: Decreased 82% to $23.3 million, largely due to the absence of $68.1 million in one-time Merger-related transaction costs incurred in 2024.
- Debt: The company entered a new $100 million loan agreement with Oxford Finance in January 2025. In March 2026 (subsequent event), this was amended to add an additional $75 million tranche.
- Net Income/Loss: Shifted from a $1.7 billion net income in 2024 (due to the Merger gain) to a $140.1 million net loss in 2025, reflecting the company's ongoing operational burn rate without the one-time transaction gain.
Guidance, Outlook, and Risks
Clinical Pipeline and Milestones
- ozekibart (INBRX-109):
- Chondrosarcoma: Met primary endpoint in the ChonDRAgon registrational trial (Oct 2025), showing a 52% reduction in risk of progression. A Biologics License Application (BLA) is planned for submission in Q2 2026.
- Ewing Sarcoma: Phase 1/2 expansion cohort showed 64.5% ORR. Enrollment expected to complete in H2 2026; FDA meeting on accelerated approval pathway planned for H2 2026.
- Colorectal Cancer: Expansion cohort showed 23% ORR. PFS data update expected Q2 2026; FDA meeting on accelerated approval planned for H2 2026.
- INBRX-106:
- HNSCC: Phase 2 enrollment (68 patients) completed Q1 2026. Initial results expected Q2 2026. Positive data may ungate a Phase 3 trial (approx. 350 patients) with PFS and OS as co-primary endpoints.
- NSCLC: Phase 1/2 enrollment (34 patients) completed Nov 2025.
Liquidity and Capital Resources
As of December 31, 2025, the company held $124.2 million in cash. Management believes this, combined with the $75 million funded in March 2026, is sufficient to fund operations for at least 12 months. The company expects to continue incurring net losses until, if ever, it achieves commercialization.
Risks and Contingencies
- Regulatory Approval: No assurance that ozekibart or INBRX-106 will receive FDA approval or that accelerated approval pathways will be granted.
- Capital Needs: Significant additional funding will be required to advance clinical trials and commercialize products. Failure to secure funding could force delays or program terminations.
- Debt Covenants: The Oxford loan agreement includes restrictive covenants, including a minimum liquidity threshold (updated to $40 million in March 2026) and limitations on dividends and additional indebtedness.
- Manufacturing: Reliance on third-party contract manufacturers for all clinical and commercial supply.
Investor Verification Checklist
- BLA Submission Timing: Verify the actual submission date of the ozekibart BLA for chondrosarcoma in Q2 2026.
- Clinical Data Readouts: Monitor Q2 2026 updates for ozekibart (Colorectal Cancer PFS) and INBRX-106 (HNSCC Phase 2 ORR) to confirm if they meet thresholds for accelerated approval discussions or Phase 3 un-gating.
- Cash Runway: Confirm the burn rate and whether the $124.2 million (plus $75 million subsequent funding) is sufficient to reach the next major value inflection point without dilutive equity raises.
- Debt Compliance: Monitor quarterly compliance with the Oxford Finance liquidity covenants ($40 million minimum).
- Commercialization Readiness: Assess the company's progress in building sales and marketing infrastructure in anticipation of a potential 2026/2027 launch.